ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-10-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 88
- Registration Number
- NCT01221077
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-09-13
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 352
- Registration Number
- NCT01199523
A Study to Evaluate the Drug Interaction of ASP015K and Tacrolimus
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-30
- Last Posted Date
- 2010-10-14
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 40
- Registration Number
- NCT01190670
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2010-10-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 16
- Registration Number
- NCT01187186
Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 205
- Registration Number
- NCT01186861
- Locations
- 🇺🇸
Site US10004, Greensboro, North Carolina, United States
🇵🇱Site PL48005, Szczecin, Poland
🇷🇴Site RO40005, Alba Iulia, Romania
A Study to Assess Drug Interaction of ASP015K and Midazolam
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-16
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01182077
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 132
- Registration Number
- NCT01181232
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Type 2 Diabetic Patients
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 168
- Registration Number
- NCT01135433
A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2012-10-15
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 26
- Registration Number
- NCT01126424
A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 44
- Registration Number
- NCT01125657
© Copyright 2024. All Rights Reserved by MedPath